Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Filter by Categories
Biosimilars Deals 2023
Biosimilars Deals 2024
Chris Vindurampulle
Other Podcasts
Other Updates
Our Awards
Patent Case Summaries
Patent Litigation
Paul Johns
Trade Marks

Harbour BioMed’s Nona Biosciences Inks US$1B Global License Agreement with Pfizer for HBM9033 (ADC)

Dec 15, 2023

Harbour BioMed’s wholly-owned subsidiary Nona Biosciences announced that it has entered into an exclusive license agreement with Pfizer for the global clinical development and commercialisation of HBM9033, Nona’s MSLN-targeted antibody-drug conjugate (ADC).  MSLN is a tumor-associated antigen upregulated in various solid tumors.  Nona will receive up to US$53M in upfront and near-term payments, with potential for payments up to US$1.05B contingent on achievement of development and commercial milestones.

In July 2023, Pfizer reached another large value deal with Samsung Biologics worth US$897M for Samsung’s manufacture of biosimilars.